Home Tags Diffuse large B-cell lymphoma

Tag: diffuse large B-cell lymphoma

U.S. FDA Accepts Biologics License Application and Grants Priority Review for...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402.The investigational agent is...

FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab...

The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab tesirine, previously know as ADCT-402,...
Featured Image: Multiple microscopic slides with stained blood smears, ready for testing. Courtesy: © Fotolia. Used with permission.

First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...

Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...

Interim Results of Phase I Clinical Trial of TRPH-222 in R/R...

The investigational drug TRPH-222 (previously known as CAT-02-106), a next-generation antibody-drug conjugate (ADC), is demonstrating early signs of efficacy in the interim results of...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Pivotal Phase II Clinical Trial of Single Agent Loncastuximab Tesirine in...

Results from a pivotal 145-patient Phase II clinical trial of loncastuximab tesirine (ADCT-402; ADC Therapeutics) for the treatment of relapsed or refractory diffuse large...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

FDA Grants Accelerated Approval of Polatuzumab Vedotin in Select Patients

The U.S. Food and Drug Administration (FDA) today confirmed that it has granted accelerated approval of polatuzumab vedotin-piiq (Polivy™; Genentech; previously known as DCDS4501A...

Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...

Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...

Polatuzumab Vedotin + Bendamustine and Rituxan Increased Complete Response Rates in...

Positive results from the randomized Phase II GO29365-study (NCT02257567) that compared polatuzumab vedotin (RG7596) in combination with bendamustine plus rituximab (Rituxan®; Genentech/Roche) against bendamustine plus...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

Updates from the 14th International Conference on Malignant Lymphoma (ICML)

Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...

Novel ADC Technology Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies...

Lymphomas, a group of cancers that originate in the lymphatic system, include both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Non-Hodgkin lymphoma, which is...